Experimental HCV Drugs
Experimental HCV Drugs
EASL 2015: Merck HCV Combination Effective after Failure of First Generation Direct-Acting Antivirals
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 23 April 2015 00:00
- Written by Keith Alcorn
Treatment for 12 weeks with grazoprevir and elbasvir, 2 direct-acting antivirals being development by Merck, plus ribavirin, cured 95% of people with hepatitis C who had experienced failure of a previous combination containing an HCV protease inhibitor, Xavier Forns of the University of Barcelona Hospital Clinic reported the at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna.
Allergy Drug Inhibits Hepatitis C Virus Replication in Mouse Study
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 17 April 2015 00:00
- Written by NIH
The over-the-counter allergy medication chlorcyclizine HCl, or CCZ, was found to be a potent inhibitor of hepatitis C virus (HCV) genotype 1b and 2a replication, according to a laboratory study described in the April 8 edition of Science Translational Medicine. The study authors suggest that this older drug could potentially be an affordable component of combination treatment. A Phase 1 clinical trial is now underway.
FDA Will Consider Approval of Daclatasvir for Genotype 3 Hepatitis C Treatment
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 17 March 2015 00:00
- Written by Bristol-Myers Squibb
The U.S. Food and Drug Administration (FDA) has accepted Bristol-Myers Squibb's application for approval of stand-alone daclatasvir (Daklinza) for the treatment of genotype 3 hepatitis C virus (HCV), to be used in combination with sofosbuvir (Sovaldi), the company announced last week.
Janssen Interferon-Free Regimen with Simeprevir Cures Most Patients with Genotype 1 HCV
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 10 April 2015 00:00
- Written by Medivir
A 12-week all-oral regimen containing the FDA-approved HCV protease inhibitor simeprevir (Olysio) plus 2 investigational direct-acting antivirals drugs being developed by Janssen cured up to 95% of people with genotype 1 hepatitis C, according to study findings presented at the Asian Pacific Association for the Study of the Liver (APASL) conference last month in Istanbul.
Coverage of the 2015 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Monday, 02 March 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.
Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.
HIVandHepatitis.com coverage by topic
3/2/15
Web Design and Development by